NDC 16729-367-46 - OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 16729-367
- Requested NDC
- 16729-367-46
- Package NDCs from labels
- 16729-367-10, 16729-367-15, 16729-367-16, 16729-367-17, 16729-367-45, 16729-367-46
- Manufacturer
- Accord Healthcare Inc. | Intas Pharmaceuticals Limited
- Effective date
- 2025-10-29
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| LACTOSE MONOHYDRATE - Accord Healthcare Inc. | Intas Pharmaceuticals Limited | Accord Healthcare Inc. | Intas Pharmaceuticals Limited | 2025-10-29 | HUMAN PRESCRIPTION DRUG LABEL |
| OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE - A-S Medication Solutions | A-S Medication Solutions | 2024-11-13 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 16729-367-10 | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | 30 in 1 BOTTLE | TABLET, FILM COATED | 30 | 7 | |
| 16729-367-15 | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | 90 in 1 BOTTLE | TABLET, FILM COATED | 90 | 7 | |
| 16729-367-16 | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | 500 in 1 BOTTLE | TABLET, FILM COATED | 500 | 7 | |
| 16729-367-17 | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | 1000 in 1 BOTTLE | TABLET, FILM COATED | 1000 | 7 | |
| 16729-367-45 | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | 10 in 1 BLISTER PACK | TABLET, FILM COATED | 10 | 7 | |
| 16729-367-46 | OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE | 100 in 1 CARTON | TABLET, FILM COATED | 100 | 7 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 16729-367-10 | EA - Each | 16729-367 | aea7451f-249f-4002-a7df-f367e3bb0513 | 1 | 2020-09-14 |
| 16729-367-15 | EA - Each | 16729-367 | 0eff996a-5135-4a4b-a09e-70ccc66334d4 | 1 | 2020-09-14 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| No7 Protect and Perfect Intense Advanced All in One Foundation SPF 50 Birch | OCTINOXATE, TITANIUM DIOIXIDE, OCTISALATE | BCM Cosmetique SAS | d5431d62-fded-4cdc-81a1-5b5e3eb92873 | 2021-06-29 | Warnings | 15FIX9V2JP |
| No7 Protect and Perfect Intense Advanced All in One Foundation SPF 50 Tawny | OCTINOXATE, TITANIUM DIOIXIDE, OCTISALATE | BCM Cosmetique SAS | 52c3378f-6b99-42fa-900e-8a693864c615 | 2021-06-29 | Warnings | 15FIX9V2JP |
| candesartan cilexetil and hydrochlorothiazide | CANDESARTAN CILEXETIL AND HYDROCHLOROTHIAZIDE | Solco Healthcare LLC | 543b9806-ccfa-4144-a2a2-d0e35eaceeee | 2021-05-21 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| Hydrochlorothiazide | HYDROCHLOROTHIAZIDE | Aphena Pharma Solutions - Tennessee, LLC | f0b993f2-9771-42e3-b10e-09719189e2bd | 2021-01-19 | Warnings, Adverse reactions | 0J48LPH2TH |
| olmesartan medoxomil | OLMESARTAN MEDOXOMIL | ScieGen Pharmaceuticals, Inc. | f15664a4-6b5f-4e88-ad56-c827ed90a40c | 2021-01-08 | Boxed warning, Warnings, Adverse reactions | 6M97XTV3HD |
| Triamterene and Hydrochlorothiazide | TRIAMTERENE AND HYDROCHLOROTHIAZIDE | Proficient Rx LP | f11598d2-87ee-4292-8631-c29c54f4dfa9 | 2021-01-01 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| Hydrochlorothiazide | HYDROCHLOROTHIAZIDE | Proficient Rx LP | 6be05675-c4b4-4e1e-9047-044a7fc7cef6 | 2021-01-01 | Warnings, Adverse reactions | 0J48LPH2TH |
| Irbesartan and Hydrochlorothiazide | IRBESARTAN AND HYDROCHLOROTHIAZIDE | Proficient Rx LP | 97b09783-7bba-4f7a-b1b3-86ccf12c7ecc | 2021-01-01 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| Losartan Potassium and Hydrochlorothiazide | LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE | Proficient Rx LP | a6e7d8a7-f969-4a21-ac28-93c77ed1fa63 | 2021-01-01 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| Valsartan and Hydrochlorothiazide | VALSARTAN AND HYDROCHLOROTHIAZIDE | Proficient Rx LP | 75b3f944-b4fc-40a5-a4e2-aec2fbab64b8 | 2021-01-01 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide | OLMESARTAN MEDOXOMIL, AMLODIPINE AND HYDROCHLOROTHIAZIDE | Teva Pharmaceuticals USA, Inc. | 5c128ef2-60a6-40f3-b37f-ee139fe27987 | 2021-01-01 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH 6M97XTV3HD |
| Hydrochlorothiazide | HYDROCHLOROTHIAZIDE | Proficient Rx LP | 78c04f59-65c3-4a16-83a6-ed4a409afce5 | 2021-01-01 | Warnings, Adverse reactions | 0J48LPH2TH |
| Losartan Potassium and Hydrochlorothiazide | LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE | Proficient Rx LP | 6dd115b5-9268-4b66-bae8-0aa2605ebbd3 | 2021-01-01 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| Losartan Potassium and Hydrochlorothiazide | LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE | Proficient Rx LP | 198d5151-7982-4639-9fe1-6573a4529348 | 2021-01-01 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| Losartan Potassium and Hydrochlorothiazide | LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE | Proficient Rx LP | 7897d182-2859-4a40-af4d-aaa9d9720fd9 | 2021-01-01 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| HYDROCHLOROTHIAZIDE | HYDROCHLOROTHIAZIDE | Aphena Pharma Solutions - Tennessee, LLC | e8ca7334-4b58-4f4b-bf36-0ab47b60ff7c | 2020-12-14 | Warnings, Adverse reactions | 0J48LPH2TH |
| Triamterene and Hydrochlorothiazide | TRIAMTERENE AND HYDROCHLOROTHIAZIDE | Aphena Pharma Solutions - Tennessee, LLC | 191b9e48-7d44-4378-9f3f-b4a999080c8c | 2020-11-12 | Warnings, Adverse reactions | 0J48LPH2TH |
| Fosinopril Sodium and Hydrochlorothiazide | FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE | CIPLA USA INC. | 4e1ed7da-029e-48d6-a5e4-fc7ac11192fb | 2020-11-03 | Boxed warning, Warnings, Adverse reactions | 0J48LPH2TH |
| HYDROCHLOROTHIAZIDE | HYDROCHLOROTHIAZIDE | Aphena Pharma Solutions - Tennessee, LLC | ec70ea28-a219-45d1-9d5b-6a79c7ef4987 | 2020-10-28 | Warnings, Adverse reactions | 0J48LPH2TH |
| hydrochlorothiazide | HYDROCHLOROTHIAZIDE | Alembic Pharmaceuticals Inc. | 841b7962-bf5d-4c45-b594-80b17ba5187d | 2020-09-11 | Warnings, Adverse reactions | 0J48LPH2TH |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.